BioCision, a Larkspur, Calif.-based developer of sample standardization tools for life science research, has raised $2.5 million in debt and equity financing, the company announced Tuesday. BroadOak Capital Partners led the round, with participation from Research Corporation Technologies. The funds will help bolster sales, marketing and development efforts.
BioCision LLC, a developer of sample standardization tools and solutions for the life science research and clinical markets, today announced it has raised $2.5 million in new growth financing. The round was led by BroadOak Capital Partners and included participation from Research Corporation Technologies, Inc. Comprised of debt and equity investment, funding will be used to support the company’s continued rapid growth and expansion of sales, marketing and product development efforts.
“BioCision’s efforts to define the pre-analytical sample handling space are impressive. Their tools add a new level of precision that advances research yet is economical and easy to understand,” said Bill Snider, managing partner, BroadOak Capital Partners. “We are glad to support BioCision and the management team, which has an opportunity to become a leader in benchtop cell cryopreservation and other sample standardization technologies.”
According Rolf Ehrhardt, MD, PhD, BioCision CEO, “Attracting leading life science investors that are focused on identifying promising, early stage companies follows numerous significant company milestones, including the launch of our novel CoolBox™ XT Workstations and a new portfolio of CoolCell® cell cryopreservation products, which include alcohol-free freezing containers, reagents and storage systems.”
BioCision is a leading provider of innovative tools for standardizing sample handling, cryopreservation and storage procedures. BioCision products are used worldwide by researchers in the pharmaceutical, biotechnology, academic and health care industries.